Related references
Note: Only part of the references are listed.Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Dawn F. Ionescu et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial*
Rodrig P. Mello et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2021)
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3
Rachel Ochs-Ross et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2020)
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study
Fernanda S. Correia-Melo et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
Elia E. Acevedo-Diaz et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Psychedelics and Psychedelic-Assisted Psychotherapy
Collin M. Reiff et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
Ziad Saad et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2020)
Deep posteromedial cortical rhythm in dissociation
Sam Vesuna et al.
NATURE (2020)
The role of dissociation in ketamine's antidepressant effects
Elizabeth D. Ballard et al.
NATURE COMMUNICATIONS (2020)
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Double-Blind, Randomized Study (ASPIRE I)
Dong-Jing Fu et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)
Ewa Wajs et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder
Seetal Dodd et al.
BIPOLAR DISORDERS (2019)
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
Dawn F. Ionescu et al.
JOURNAL OF AFFECTIVE DISORDERS (2019)
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Maggie Fedgchin et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial
Ella J. Daly et al.
JAMA PSYCHIATRY (2019)
Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression
I. Esterlis et al.
MOLECULAR PSYCHIATRY (2018)
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
Mark J. Niciu et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression A Randomized Clinical Trial
Ella J. Daly et al.
JAMA PSYCHIATRY (2018)
The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes
Victor Chavarria et al.
CLINICAL THERAPEUTICS (2017)
Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study
Y. -D. Hu et al.
PSYCHOLOGICAL MEDICINE (2016)
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
Jaskaran B. Singh et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study
Jaskaran B. Singh et al.
BIOLOGICAL PSYCHIATRY (2016)
Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant
Elizabeth D. Ballard et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2015)
Do the dissociative side effects of ketamine mediate its antidepressant effects?
David A. Luckenbaugh et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
Therapeutic Drug Monitoring (TDM) in Psychiatry (Part I): Why Studies Attempting to Correlate Drug Concentration and Antidepressant Response Don't Work
Sheldon H. Preskorn
JOURNAL OF PSYCHIATRIC PRACTICE (2014)
Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety
Elizabeth D. Ballard et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2014)
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
James W. Murrough et al.
BIOLOGICAL PSYCHIATRY (2013)
Direct and Indirect Effects in a Survival Context
Theis Lange et al.
EPIDEMIOLOGY (2011)
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS
Gerald W. Valentine et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2011)
A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
Nancy Diazgranados et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Rapid Resolution of Suicidal Ideation After a Single Infusion of an N-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder
Nancy DiazGranados et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
A General Approach to Causal Mediation Analysis
Kosuke Imai et al.
PSYCHOLOGICAL METHODS (2010)
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Rebecca B. Price et al.
BIOLOGICAL PSYCHIATRY (2009)
An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
Sheldon H. Preskorn et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Flat dose-response curves for efficacy: What do they mean to the clinician?
Sheldon H. Preskorn
JOURNAL OF PSYCHIATRIC PRACTICE (2008)
Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy -: a [123I]CNS-1261 SPET study
James M. Stone et al.
PSYCHOPHARMACOLOGY (2008)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Carlos A. Zarate et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Antidepressant effects of ketamine in depressed patients
RM Berman et al.
BIOLOGICAL PSYCHIATRY (2000)
Share Paper
